Inovio completes enrollment in late-stage of VGX-3100 in HPV

Inovio Pharmaceuticals (NASDAQ:INO) has completed target enrollment of 198 participants for its Phase 3 registration trial (“REVEAL 1”) of VGX-3100, a DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV).

A confirmatory Phase 3 trial (REVEAL 2) is currently enrolling with FDA submission expected in 2021.

The primary endpoint of the Phase 3 study is regression of cervical HSIL and virologic clearance of HPV 16 and/or HPV 18 in the cervix.

The studies will evaluate cervical tissue changes at approx. 9 months after beginning a three dose regimen administered at months 0, 1, and 3.

Shares are up 5% premarket.

https://seekingalpha.com/news/3473894-inovio-completes-enrollment-late-stage-vgxminus-3100-hpv-shares-5-percent-premarket